3 days ago
NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science.
As NetraMark strategically expands its footprint in the pharmaceutical industry, this appointment reinforces the Company's commitment to scaling its offerings across psychiatry, oncology and other high-growth therapeutic areas. The global addressable market for AI-driven clinical trial optimization is projected to continue to expand rapidly, and NetraMark seeks to continue to capture market share with its proprietary technology and growing commercial pipeline.
